Blueprint Medicines price target raised to $55 from $48 at Wells Fargo

Wells Fargo analyst Derek Archila raised the firm’s price target on Blueprint Medicines to $55 from $48 and keeps an Equal Weight rating on the shares. While the firm’s recent allergist/immunologist survey was generally positive for Blueprint Medicines’ ongoing Ayvakit launch in ISM and its revenue estimates/price target do move up a bit, Wells thinks shares largely reflect this.